1.46
Allogene Therapeutics Inc stock is traded at $1.46, with a volume of 2.90M.
It is down -5.81% in the last 24 hours and down -25.13% over the past month.
Allogene Therapeutics Inc is a clinical-stage biotech firm specializing in immuno-oncology, focusing on the development of genetically engineered allogeneic T-cell products for cancer and autoimmune diseases. Their pipeline includes off-the-shelf T-cell candidates designed to target cancer cells or autoreactive cells in autoimmune disorders. Notably, their allogeneic approach, derived from healthy donors, allows for broader patient eligibility and scalability. With a vision to redefine CAR T therapy, the company concentrates on core programs targeting lymphoma, leukemia, autoimmune diseases, and solid tumors. Revenue, generated from collaborations and licensing agreements, supports their research and development efforts.
See More
Previous Close:
$1.55
Open:
$1.5
24h Volume:
2.90M
Relative Volume:
0.56
Market Cap:
$316.12M
Revenue:
$95,000
Net Income/Loss:
$-327.27M
P/E Ratio:
-0.6887
EPS:
-2.12
Net Cash Flow:
$-239.25M
1W Performance:
-13.10%
1M Performance:
-25.13%
6M Performance:
-47.86%
1Y Performance:
-67.34%
Allogene Therapeutics Inc Stock (ALLO) Company Profile
Name
Allogene Therapeutics Inc
Sector
Industry
Phone
(650) 457-2700
Address
210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO
Compare ALLO with other stocks
Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
---|---|---|---|---|---|---|
![]()
ALLO
Allogene Therapeutics Inc
|
1.46 | 316.12M | 95,000 | -327.27M | -239.25M | -2.12 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
484.82 | 131.41B | 11.02B | -535.60M | -978.00M | -2.20 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
634.23 | 72.26B | 14.20B | 4.41B | 3.54B | 38.28 |
![]()
ARGX
Argen X Se Adr
|
591.87 | 36.10B | 2.19B | 833.04M | -1.28B | 12.71 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
270.02 | 35.03B | 2.25B | -278.16M | -42.59M | -2.17 |
![]()
ONC
Beigene Ltd Adr
|
272.17 | 28.24B | 3.81B | -644.79M | -669.77M | -6.24 |
Allogene Therapeutics Inc Stock (ALLO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Mar-14-25 | Upgrade | Citizens JMP | Mkt Perform → Mkt Outperform |
Aug-08-24 | Resumed | Oppenheimer | Outperform |
May-31-24 | Initiated | Piper Sandler | Overweight |
Jan-05-24 | Downgrade | Guggenheim | Buy → Neutral |
Jan-05-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
Dec-08-23 | Initiated | Citigroup | Buy |
Jun-26-23 | Resumed | Oppenheimer | Outperform |
Mar-21-23 | Initiated | Bernstein | Mkt Perform |
Jan-24-23 | Upgrade | JP Morgan | Neutral → Overweight |
Jan-06-23 | Upgrade | Robert W. Baird | Neutral → Outperform |
Dec-12-22 | Downgrade | BofA Securities | Buy → Underperform |
Aug-10-22 | Downgrade | Raymond James | Outperform → Mkt Perform |
Jul-15-22 | Upgrade | Goldman | Neutral → Buy |
Jun-03-22 | Initiated | Robert W. Baird | Neutral |
Feb-28-22 | Reiterated | B. Riley Securities | Buy |
Oct-20-21 | Initiated | Cowen | Outperform |
Oct-08-21 | Downgrade | Goldman | Buy → Neutral |
Oct-08-21 | Downgrade | Stifel | Buy → Hold |
Sep-23-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
Jun-21-21 | Resumed | Jefferies | Buy |
May-20-21 | Upgrade | Truist | Hold → Buy |
May-14-21 | Initiated | B. Riley Securities | Buy |
Jan-26-21 | Upgrade | Stifel | Hold → Buy |
Dec-10-20 | Resumed | H.C. Wainwright | Buy |
Nov-24-20 | Initiated | BofA Securities | Buy |
Oct-23-20 | Initiated | RBC Capital Mkts | Outperform |
Jun-01-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
May-29-20 | Reiterated | H.C. Wainwright | Buy |
May-19-20 | Upgrade | ROTH Capital | Neutral → Buy |
May-15-20 | Upgrade | Guggenheim | Neutral → Buy |
May-14-20 | Reiterated | H.C. Wainwright | Buy |
May-14-20 | Downgrade | SunTrust | Buy → Hold |
Apr-13-20 | Initiated | SunTrust | Buy |
Mar-13-20 | Initiated | H.C. Wainwright | Buy |
Mar-05-20 | Initiated | Stifel | Hold |
Feb-24-20 | Initiated | Berenberg | Hold |
Dec-18-19 | Initiated | JMP Securities | Mkt Outperform |
Nov-04-19 | Initiated | Canaccord Genuity | Buy |
Aug-09-19 | Initiated | BTIG Research | Buy |
Jun-05-19 | Initiated | ROTH Capital | Neutral |
May-31-19 | Initiated | Guggenheim | Neutral |
May-23-19 | Initiated | Stifel | Hold |
Mar-29-19 | Initiated | Piper Jaffray | Overweight |
View All
Allogene Therapeutics Inc Stock (ALLO) Latest News
H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating By Investing.com - Investing.com South Africa
H.C. Wainwright cuts Allogene stock target to $8, keeps Buy rating - Investing.com India
Allogene Therapeutics CEO sells $91,469 in stock By Investing.com - Investing.com Australia
Allogene Therapeutics CEO sells $91,469 in stock - Investing.com India
Allogene Therapeutics Executives Sell Shares for Tax Obligations - TradingView
Renal Cancer Clinical Pipeline | 75+ Companies, Including - openPR.com
7th Annual Allogeneic Cell Therapies Summit - pharmaphorum
Allogene Therapeutics' SWOT analysis: CAR-T pioneer's stock faces pivotal year - Investing.com
Allogene Therapeutics’ SWOT analysis: CAR-T pioneer’s stock faces pivotal year - Investing.com India
Allogeneic T Cell Therapies Market Set For 9.8% Growth, Reaching $1.9 Billion By 2029 - WhaTech
Allogene upgraded at Citizens after Q4 update - MSN
Allogene Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Allogene Therapeutics, Inc. (NASDAQ:ALLO) Q4 2024 Earnings Call Transcript - Insider Monkey
Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... By GuruFocus - Investing.com Canada
Citizens Capital Markets Upgrades Allogene Therapeutics (ALLO) - Nasdaq
Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlights: Financial Challenges Amid ... - Yahoo
Allogene Therapeutics Inc (ALLO) Q4 2024 Earnings Call Highlight - GuruFocus.com
Citi maintains Buy on Allogene stock with $8 price target By Investing.com - Investing.com Australia
Allogene stock upgraded at Citizens post Q4 (ALLO:NASDAQ) - Seeking Alpha
Citi maintains Buy on Allogene stock with $8 price target - Investing.com India
Allogene's Q4 Loss Narrower Than Expected, Revenues Nil - Yahoo Finance
Allogene Therapeutics: Q4 Earnings Snapshot - The Wilton Bulletin
Earnings call transcript: Allogene’s Q4 2024 earnings beat expectations By Investing.com - Investing.com South Africa
Earnings call transcript: Allogene’s Q4 2024 earnings beat expectations - Investing.com India
Allogene Therapeutics Inc Q4 Loss Per Share $0.28 -March 13, 2025 at 05:32 pm EDT - Marketscreener.com
Allogene Therapeutics Inc Reports Q4 2024 EPS of -$0.28, Beating Estimates; Revenue Falls Short - GuruFocus.com
Allogene Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
ALLOGENE THERAPEUTICS Earnings Results: $ALLO Reports Quarterly Earnings - Nasdaq
Allogene Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Update - The Manila Times
Allogene Therapeutics: Q4 Earnings Snapshot -March 13, 2025 at 05:05 pm EDT - Marketscreener.com
Allogene Therapeutics, Inc. to Host Earnings Call - ACCESS Newswire
CAR T-cell Therapy Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 180+ Companies Working in the Domain - Yahoo Finance
CAR T-cell Therapy Clinical Trial Pipeline Experiences - GlobeNewswire
Foresight Diagnostics expands Allogene partnership - BizWest
Allogene Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update - The Manila Times
When Will Allogene Reveal Its CAR T Progress? Key Earnings Date Set - StockTitan
Allogene Therapeutics Schedules Conference Call and Webcast for Q4 and Full Year 2024 Financial Results on March 13, 2025 - Nasdaq
Foresight Diagnostics Expands Strategic Partnership with Allogene Therapeutics to Advance Joint Development Activities Outside of the U.S. Across Europe, UK, Canada and Australia - The Malaysian Reserve
Allogene Short Interest Reportedly Near 5-Year Lows Amid Growing Retail Optimism: Analyst Sees CAR-T Therapy Promise - MSN
Allogene: Assessing The Pipeline, Competitive Landscape, And Opportunities (NASDAQ:ALLO) - Seeking Alpha
Allogene Expands Partnership With Foresight Diagnostics To Advance Cema-Cel Development Globally - Nasdaq
Allogene Therapeutics Announces Participation in March Investor Conference - The Manila Times
Allogene Therapeutics Inc Stock (ALLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):